Gavi

www.gavi.org
CONSENT AGENDA
BOARD MEETING
22-23 June 2022, Geneva, Switzerland
Reach every child
Recommendation 1: Consent Agenda: Board
Committee Chair Appointments
2
TheGavi Alliance Governance Committeerecommends tothe Gavi Alliance Boardthat
it :
Appoint Anne Schuchat asChair ofthe Programme andPolicy Committee effective
1 July 2022 anduntil 31December 2023.
Board meeting
22- 23 June 2022

Gavi

Gavi

Gavi

Gavi

Gavi

Gavi

Gavi

Gavi

1



Board -2022 -Mtg -02-Doc 08
Report to the Board
22 -23 June 202 2


Section A: Executive Summary
Context
Malaria remains one of the deadliest diseases for children under five years old,
particularly those living in communities facing multiple deprivation s and exclusion.
In 2020 al one, there were an estimated 241 million malaria cases in 85 malaria
endemic countries increasing from 227 million in 2019, with the WHO Af rican
Region accounting for most of the increase. Approximately 96% of malaria cases
and deaths globally in 2020 were in 29 countries ? out of which 2 8 are Gavi -eligible
countries. In December 2021, the Gavi Alliance Board approved support
(US$ 155.7 million for the 2022 -2025 period) for a malaria vaccine programme to
enable the introduction of malaria vaccines as part of a comprehensive approach
to malaria control in malaria -endemic countries. The Board also requested the
Secretariat and Alliance part ners to coordinate with countries, the Global Fund and
other malaria stakeholders to design and implement a malaria vaccine programme
including key consideration s such as country eligibility, optimal mix of malaria
interventions, allocation of scar ce suppl y and country financing . Concurrent to the
ongoing design of Gavi?s malaria vaccine programme, the Malaria Vaccine
Implementation Programme (MVIP) continues to evaluate various aspects of
programme implementation in Ghana, Malawi and Kenya.
Question s this paper addresses
What progress has been made in the design of the malaria vaccine programme?
Conclusions
The d esign of Gavi?s malaria vaccine programme has advanced : the framework
for the allocation of limited vaccine supply is on course to be finalised in June 2022 ;
malaria vaccine funding guidelines are being developed and will be integrated with
the new Gavi Application Funding guidelines and launched in July 2022; guidelines
for country co -financing of the malaria vaccine are being prepared as part of the
Funding Policy Review and will be presented and finalised by the Programme and
Policy Committee ( PPC ) and Board at the end of 2022; and market shaping work
progress es with the market shaping roadmap and UNICEF S upply Division tender
to both be completed in Q3 2022. Additionally, implementation of the MVIP
continues and provide s valuable lessons to inform programme design for broader
scale -up of the vaccine.
SUBJECT : UPDATE ON MALARIA VACCINE PROGRAMME
Agenda item: 08
Category: For Guidance

1


Re port to the Board

Board -2022 -Mtg -02-Doc 09 -Annex A
Annex A: Implications/Anticipated impact
Risk implication and mitigation: There are two key risks to the MICs Approach.
The first is that the Secretariat does not have the capacity to deliver successfull y
given limited bandwidth. This is mitigated through the resources for implementation
designated within the MICs Approach budget. Without these resources, the MICs
Approach would not be able to reach its full potential.
The second risk is the continued unc ertainty around the COVID -19 pandemic and
its impact on countries , potentially limiting the extent to which they are able to
engage . This is mitigated by building and strengthening the enabling environment,
investing at the regional and global level to address common challenges and
shared bottlenecks, while standing ready to deploy targeted and catalytic tools at
the country level.
Ris k of inaction: As of early 2021, c ountries have started to express renewed
interest in the introduction of PCV, rotavirus and HPV vaccine s. With out the
support through the MICs Approach , there is a risk that these introductions are not
achieved, as countri es would have less support to overcome the barriers impeding
progress. Should these introductions be achieved, there is a risk that they are less
sustainable and equitable than they could otherwise be with support through the
MICs Approach, with marginalis ed and vulnerable population subgroups most at
risk of being left behind.
Without the support through the MICs Approach t here is also a risk of further
backsliding in routine immunisation coverage in former -Gavi countries that would
undermine prior investments and achievements. There is also a risk that the zero -
dose population in former -Gavi countries would remain unreached , and potentially
even continue to grow larger.
Impact on countries: The MICs Approach is critical to helping build the
ecosystems necessary to introduce life -saving vaccines and sustain immunisation
programme performance. When combined with targeted and c atalytic tools, t he
Secretariat believes that the MICs Approach could drive the sustainable and
equitable introduction of 8 -10 new vaccines by 2025, reaching 4 million -6 million
new children or adolescents. It could also help contribute toward the restorat ion of
routine immunisation coverage in former -Gavi countries following the significant
impact incurred within the context of the pandemic. W ith its specific focus on
reaching zero -dose children in reinforcement of routine immunisation services, the
MICs Approach could reduce the overall number of zero -dose children in former -
Gavi countries by 15%, equivalent to approximately 230,000 children.
Finally, the MICs Approach could also have a significant impact on the lives of
children in fragile MICs subject to countries meeting the conditions and receiving
support .
Impact on Alliance: The Alliance continues to be strained amid the COVID -19
pandemi c and may have limited capacity to implement the MICs Approach. This is
mitigated by the provision of support , accessible to partners at the country and
regional level , to enable delivery of the MICs Approach.